MedTrace Logo

The Effects of Fentanyl Abuse on Executive Function and Related Brain Activity

NCT05469217 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2022-07-21

No results posted yet for this study

Summary

There is a widespread abuse of prescription opioids and a dramatic increase in the availability of illicit opioids. These have created the "opioid epidemic" which is one of the most severe public health crisis in US History. Fentanyl, a synthetic opioid that is 50 to 100 times more potent than morphine, is a schedule II prescription drug used to treat severe pain. It is also a drug of abuse. Fentanyl is more likely to cause an overdose than is heroin because of its greater potency. In addition, it has a shorter half-life than most other opioids, causing the high to fade more quickly, requiring opioid drug abusers to inject more frequently, and increasing the risk of overdose. There is an increasing use of Fentanyl in Israel, and one of the treatment centers has reported that on average each month over the last year 10 patients that have used fentanyl were admitted. We propose to investigate executive function using established tasks such as the N-back and Go No Go tasks as well as structural brain imaging of gray matter volume and white matter tracts in 15 fentanyl abuse patients that will be compared with 15 healthy control participants.

Conditions

  • Fentanyl Dependence

Interventions

OTHER

fMRI brain imaging

Structural MRI of gray and white matter, functional MRI during performance of the N-back task

Sponsors & Collaborators

  • Sheba Medical Center

    collaborator OTHER_GOV

  • Ariel University

    lead OTHER

Principal Investigators

  • Galia Zarfati, MD · Sheba Tel Hashomer Medical Center

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-30
Primary Completion
2024-09-30
Completion
2025-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05469217 on ClinicalTrials.gov